Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase CBLL2 (CBLL2) is an enzyme that belongs to the zinc finger protein family, containing both a RING-type and a C2H2-type zinc finger domain. CBLL2 catalyzes the ubiquitination of substrate proteins, tagging them for degradation via the ubiquitin-proteasome system. It is expressed in multiple tissues with prominent localization in the testis, implicating a possible role in human sperm production and quality control. While E3 ubiquitin ligases as a family play a critical part in protein turnover, signal transduction, and cellular homeostasis, specific mechanistic details of CBLL2’s disease associations or therapeutic potential are less well-established but may include cancer and reproductive biology due to its enzyme class’s function. No direct drugs or clinical interventions currently target CBLL2 specifically, but E3 ligases are increasingly recognized as key therapeutic nodes in targeted protein degradation strategies.
Indirect enzyme inhibition or targeted protein degradation; general mechanisms for E3 ubiquitin ligase inhibitors or PROTACs, but none specific to CBLL2 are available
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase CBLL2 (CBLL2).